Editas Medicine, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 8EM.F | SCTX | PRQR | NTLA | DTIL | CRSP | |
|---|---|---|---|---|---|---|
| Market cap | 359.38M | 317.67M | 198.98M | 1.72B | 226.84M | 5.02B |
| P/E (TTM) | — | — | — | — | 32.5 | — |
| Forward P/E | -0.7 | -4.6 | -3.0 | -4.8 | -4.4 | -14.4 |
| Price/book | 3.8 | -0.3 | 2.2 | 2.4 | 4.4 | 3.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −7.94% | −11.54% | −36.20% | −0.08% | +26.09% | −8.54% |
| Today | +3.54% | +3.58% | +2.92% | +3.79% | +16.50% | +3.57% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 8EM.F news ›Financial Contrast: Alvotech (NASDAQ:ALVO) & Editas Medicine (NASDAQ:EDIT)
Posted by Michael Walen on Oct 18th, 2026 Alvotech (NASDAQ:ALVO – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two…
Editas Medicine (NASDAQ:EDIT) Stock Breaks Below 50 Day Moving Average – Here’s Why
Posted by Defense World Staff on Oct 17th, 2026 Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) crossed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $2.83 and traded as low…
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
Editas Medicine (EDIT) will present two posters at the European Society of Gene and Cell Therapy Congress on October 28, 2026. Editas Medicine (EDIT) will present two posters at the European Society of Gene and Cell Therapy Congress on…
Editas Medicine, Inc. (NASDAQ:EDIT) Stock Has Average Target Price of $5.80
Posted by Tristan Rich on Oct 10th, 2026 Get Our Latest Report on EDIT Shares of EDIT stock opened at $2.90 on Monday. The firm has a 50-day moving average of $2.86 and a 200-day moving average of $2.89. Editas Medicine has a one year low…
Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027
Editas Medicine (EDIT) was on investors’ radar on Thursday after Australian authorities cleared the biotech firm’s experimental gene-editing treatment for its first human clinical trial, prompting Wells Fargo to upgrade the stock. EDIT…
Editas Medicine’s EDIT-401 cleared for clinic in Australia
Editas Medicine Inc. has received approval in Australia to initiate a first-in-human trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia. The phase I/II Strive trial has received Human Research Ethics Committee…
Editas Medicine (NASDAQ:EDIT) Raised to Overweight at Wells Fargo & Company
Check Out Our Latest Analysis on Editas Medicine Editas Medicine, Inc is a biotechnology company focused on developing genomic medicines that use CRISPR-based gene-editing technologies to treat diseases caused by genetic abnormalities. The…
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
New Zealand enrollment remains conditional on approval, while the Australian trial has completed its ethics and notification steps. Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com3
- marketbeat.com2
- defenseworld.net1
- globenewswire.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.